MZT2A

Across TCGA pan-cancer cohorts, MZT2A RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of MZT2A’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where MZT2A RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MZT2A is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

KIRC, KIRP, and COAD are the cancer types where MZT2A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MZT2A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	III,IV	+1.887	<.001	12	view →
KIRP	Female	II,III,IV	+1.560	<.001	11	view →
COAD	Female	II,III,IV	+1.465	<.001	11	view →
BLCA	Male	IV	+1.107	<.001	11	view →
LUAD	All	III,IV	+0.930	<.001	9	view →
LUSC	Female	All	+1.572	<.001	8	view →
HNSC	Male	IV	+1.122	<.001	8	view →
LIHC	Female	II,III,IV	+0.945	<.001	7	view →
STAD	Male	II,III,IV	+0.795	<.001	7	view →
BRCA	All	III,IV	+1.024	<.001	6	view →
CHOL	All	All	+2.104	<.001	5	view →
KICH	Female	All	−1.190	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

MZT2A–KIRC

Open the KIRC breakdown →